The merger is on track for closing, but the preclinical data are too preliminary to affect valuation. Monitor for IND submission and first-in-human trial initiation in 2027, as well as any regulatory updates on the merger.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Oct 30 $1.40entry
- T+1 · 15d ago 0.00%α +0.48% · $1.40
- T+5 · 11d ago −1.43%α +1.27% · $1.38
- T+11 · todayOpen
- T+20 · in 13d Pending
- T+60 · in 2mo Pending
Price Chart
How similar events traded
Executive Summary
Eos SENOLYTIX reported early interim preclinical data for PTC-2105 in aged rats, showing preserved motor performance and reduced fat mass, consistent with prior mouse studies. The filing also confirms that Pulmatrix stockholders approved the proposed merger on October 26, 2026, with closing expected shortly in Q4 2026. The data are preliminary and promotional, with no changes to deal terms or financials.
Key Financial Metrics
Key Facts
- Interim rat study data: Rotarod latency preserved near baseline with PTC-2105 0.5 mg/kg vs. -76% decline with vehicle (p=0.012, n=3 and n=4).
- Fat mass decreased 14.5% from baseline with PTC-2105 12.5 mg/kg vs. 8.2% with vehicle at Week 8 (p=0.018, n=8 per group).
- PTC-2105 well tolerated with no adverse safety signals observed to date.
- Pulmatrix stockholders approved the merger with Eos SENOLYTIX on October 26, 2026.
- Merger anticipated to close shortly in Q4 2026, subject to customary closing conditions.
- Combined company expected to trade on Nasdaq under ticker MTXL.
- First-in-human trials for PTC-2105 targeted for 2027, subject to IND clearance.
Financial Impact
No financial figures disclosed; preclinical data are early stage and promotional.
Risk Factors
- Preclinical results may not translate to clinical outcomes.
- Merger closing subject to customary conditions; risk of delay or failure.
- PTC-2105 has not been approved by FDA for any indication.
- Company depends on license from SENOTHERAPEUTIX, Inc.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001493152-26-049353 |
| Document: 0001493152-26-049353-index-headers.html | 0001493152-26-049353 |
| Document: 0001493152-26-049353-index.html | 0001493152-26-049353 |
| Document: 0001493152-26-049353.txt | 0001493152-26-049353 |
Track record
21 reports on PULM
6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +15.29% at T+60 after the Aug 7, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 9, 20267d ago 425 Neutral 3/10 Entry $1.36 to $1.33 Now $1.33 −1.85% ▼ −1.84% −0.15% vs SPY
- Oct 30, 202617d ago 425 Neutral 3/10 Viewing Entry $1.40 to $1.38 Now $1.33 −5.00% ▼ −1.43% +1.27% vs SPY
- Oct 23, 202625d ago EFFECT Bearish 5/10 Entry $1.48 to $1.40 Now $1.33 +10.14% ▲ +5.41% +4.85% vs SPY
- Oct 22, 202625d ago 425 Neutral 4/10 Entry $1.42 to $1.41 Now $1.33 −6.34% ▼ −0.70% −1.41% vs SPY
- Oct 13, 20264w ago 425 Neutral 4/10 Entry $1.38 to $1.43 Now $1.33 −3.62% ▲ +3.62% +4.77% vs SPY
- Oct 7, 20265w ago DEFA14A Neutral 2/10 Entry $1.53 to $1.41 Now $1.33 −12.91% ▼ −7.67% −7.39% vs SPY
- Oct 2, 20266w ago S-3/A Bearish 5/10 Entry $1.48 to $1.43 Now $1.33 +10.14% ▲ +3.38% +3.80% vs SPY
- Sep 28, 20267w ago EFFECT Bearish 5/10 Entry $1.59 to $1.48 Now $1.33 +16.35% ▲ +6.92% +8.12% vs SPY
- Sep 25, 20267w ago DEFM14A Bearish 6/10 Entry $1.59 to $1.48 Now $1.33 +16.35% ▲ +6.92% +8.12% vs SPY
- Sep 23, 20267w ago S-4/A Neutral 2/10 Entry $1.67 to $1.54 Now $1.33 −20.36% ▼ −7.78% −7.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers